The FSBI RCMG Genome Editing Laboratory continues to enrich its collection of stem cells from cystic fibrosis patients
The researchers at the Genome Editing and Mutagenesis laboratories and Biobank SRC derived and fully characterized another culture of induced pluripotent stem cells from a cystic fibrosis female patient. The derived stem cell line was the fourth in the laboratory's collection. Like the previous lines, it was derived by reprogramming the fibroblasts from a cystic fibrosis female patient with a homozygous F508del mutation in the CFTR gene. This time, the researchers used a new method of reprogramming – a non-integrating mRNA vector with Yamanaka factors, which is deemed one of the safest. Stem Cell Research journal (Q1, impact factor 4.489) published the information on the process of creation and characterization of the line, and the European Registry of Human Stem Cells registered the line itself.
Kondrateva E., Demchenko A., Slesarenko Y., Yasinovsky M., Amelina E., Tabakov V., Voronina E., Lavrov A., Smirnikhina S. Derivation of iPSC line (RCMGi002-A) from dermal fibroblasts of a cystic fibrosis female patient with homozygous F508del mutation. Stem Cell Research, 2021, Volume 53, 102251, DOI: 10.1016/j.scr.2021.102251.